Matinas BioPharma Holdings, Inc.
MTNB
$0.591
-$0.053-8.23%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | -100.00% | -100.00% | -65.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -100.00% | -100.00% | -100.00% | -65.63% |
| Cost of Revenue | -21.10% | -13.41% | -8.78% | -10.89% | -13.13% |
| Gross Profit | 14.64% | -1.51% | -15.96% | -22.65% | 0.72% |
| SG&A Expenses | -15.86% | -14.21% | -7.60% | -8.58% | -6.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.91% | -13.75% | -8.29% | -9.93% | -10.50% |
| Operating Income | 15.17% | 5.78% | -4.74% | -7.26% | 3.35% |
| Income Before Tax | -6.05% | 0.61% | -10.85% | -13.25% | -9.26% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.71% | 0.61% | -10.85% | -13.25% | -9.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.71% | 0.61% | -10.85% | -13.25% | -9.26% |
| EBIT | 15.17% | 5.78% | -4.74% | -7.26% | 3.35% |
| EBITDA | 15.33% | 5.81% | -4.82% | -7.32% | 3.55% |
| EPS Basic | 5.44% | 6.98% | -7.12% | -13.01% | -8.96% |
| Normalized Basic EPS | 21.64% | 6.98% | -7.12% | -13.01% | -8.96% |
| EPS Diluted | 5.44% | 6.98% | -7.12% | -13.01% | -8.96% |
| Normalized Diluted EPS | 21.64% | 6.98% | -7.12% | -13.01% | -8.96% |
| Average Basic Shares Outstanding | 11.96% | 7.91% | 3.92% | 0.27% | 0.33% |
| Average Diluted Shares Outstanding | 11.96% | 7.91% | 3.92% | 0.27% | 0.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |